Document is current
Any future updates will be listed below
-
Authors
Truxova, Iva
Cibula, David https://orcid.org/0000-0001-6387-9356
Spisek, Radek
Fucikova, Jitka https://orcid.org/0000-0002-8423-479X
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02477644 at ClinicalTrials.govnct02760797 at ClinicalTrials.govDocuments that mention this clinical trial
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
https://doi.org/10.1136/ijgc-2020-001288
Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review
https://doi.org/10.1136/ijgc-2019-001041
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer
https://doi.org/10.1136/ijgc-2018-000071
Efficacy of subsequent therapies in patients (pts) with advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial according to whether disease progression occurred during or after the end of olaparib (ola) maintenance.
https://doi.org/10.1200/jco.2023.41.16_suppl.5550
Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies
https://doi.org/10.1136/ijgc-2019-000499
DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment
https://doi.org/10.1136/ijgc-2020-001694
FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited
https://doi.org/10.1016/j.ygyno.2016.06.013
Outcomes and endpoints of relevance in gynecologic cancer clinical trials
https://doi.org/10.1136/ijgc-2022-003727
Interviews conducted at the European Society of Gynaecological Oncology 2022 Congress: a ENYGO-IJGC Fellows initiative
https://doi.org/10.1136/ijgc-2022-004160
Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study
https://doi.org/10.1136/ijgc-2019-000512
Targeting the hallmarks of ovarian cancer: The big picture
https://doi.org/10.1016/j.ygyno.2016.03.037
Best original research presented at the 24th European Congress on Gynaecological Oncology—Best of ESGO 2023
https://doi.org/10.1136/ijgc-2023-005132
167 Safety and quality of life of first-line maintenance olaparib plus bevacizumab in older patients with advanced ovarian cancer in the PAOLA-1 trial
https://doi.org/10.1136/ijgc-2021-esgo.346
Pathologic response to neoadjuvant chemotherapy in advanced ovarian cancer: utility of a scoring system to predict outcomes
https://doi.org/10.1136/ijgc-2019-000232
Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis
https://doi.org/10.1136/ijgc-2022-003614
Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy plus bevacizumab
https://doi.org/10.1136/ijgc-2019-esgo.10
#528 Efficacy of subsequent chemotherapy followed by PARP inhibitor maintenance in patients with advanced ovarian cancer in the phase III PAOLA-1/ENGOT-Ov25 trial
https://doi.org/10.1136/ijgc-2023-esgo.30
18 Efficacy of maintenance olaparib plus bevacizumab by biomarker status in clinical higher- and lower-risk patients with newly diagnosed, advanced ovarian cancer in the PAOLA-1 trial
https://doi.org/10.1136/ijgc-2020-igcs.18
New windows of surgical opportunity for gynecological cancers in the era of targeted therapies
https://doi.org/10.1136/ijgc-2023-004580
Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial
https://doi.org/10.1200/po.22.00258
2022-RA-935-ESGO Development of an academic genomic instability score for ovarian cancers
https://doi.org/10.1136/ijgc-2022-esgo.596
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial
https://doi.org/10.1136/ijgc-2023-004995
<i>BRCA1</i> and <i>RAD51</i> methylation impact on outcome in patients with advanced ovarian cancer: A PAOLA-1 ancillary study.
https://doi.org/10.1200/jco.2023.41.16_suppl.5559
nct02718911 at ClinicalTrials.govDocuments that mention this clinical trial
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients
https://doi.org/10.1136/jitc-2020-001153
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
nct01525602 at ClinicalTrials.govDocuments that mention this clinical trial
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
nct02452424 at ClinicalTrials.govDocuments that mention this clinical trial
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine
https://doi.org/10.1016/j.ygyno.2015.12.030
nct02923739 at ClinicalTrials.govDocuments that mention this clinical trial
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine
https://doi.org/10.1016/j.ygyno.2015.12.030
Immunotherapy for sarcomas: new frontiers and unveiled opportunities
https://doi.org/10.1136/jitc-2020-001580
Neuroblastoma: an ongoing cold front for cancer immunotherapy
https://doi.org/10.1136/jitc-2023-007798
nct02526017 at ClinicalTrials.govDocuments that mention this clinical trial
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
nct00537368 at ClinicalTrials.govDocuments that mention this clinical trial
Mirage or long-awaited oasis: reinvigorating T-cell responses in pancreatic cancer
https://doi.org/10.1136/jitc-2020-001100
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
Neuroblastoma: an ongoing cold front for cancer immunotherapy
https://doi.org/10.1136/jitc-2023-007798
nct01204996 at ClinicalTrials.govDocuments that mention this clinical trial
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
nct01248949 at ClinicalTrials.govDocuments that mention this clinical trial
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
nct01493505 at ClinicalTrials.govDocuments that mention this clinical trial
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
nct01688206 at ClinicalTrials.govDocuments that mention this clinical trial
A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery
https://doi.org/10.1016/j.ejca.2014.06.010
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
Targeting the hallmarks of ovarian cancer: The big picture
https://doi.org/10.1016/j.ygyno.2016.03.037
Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma—Mechanistics, review of phase III randomized clinical trials, and regulatory implications
https://doi.org/10.1016/j.ygyno.2013.11.029
Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper
https://doi.org/10.1016/j.ygyno.2013.11.008
nct04691375 at ClinicalTrials.govDocuments that mention this clinical trial
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
Neutrophils in the era of immune checkpoint blockade
https://doi.org/10.1136/jitc-2020-002242
nct00319748 at ClinicalTrials.govDocuments that mention this clinical trial
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
nct01294293 at ClinicalTrials.govDocuments that mention this clinical trial
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
nct01666444 at ClinicalTrials.govDocuments that mention this clinical trial
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
nct00319748 at ClinicalTrials.govDocuments that mention this clinical trial
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine
https://doi.org/10.1016/j.ygyno.2015.12.030
nct01666444 at ClinicalTrials.govDocuments that mention this clinical trial
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
nct01666444 at ClinicalTrials.govDocuments that mention this clinical trial
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine
https://doi.org/10.1016/j.ygyno.2015.12.030
nct02554812 at ClinicalTrials.govDocuments that mention this clinical trial
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine
https://doi.org/10.1016/j.ygyno.2015.12.030
nct02637531 at ClinicalTrials.govDocuments that mention this clinical trial
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2022-005471
nct03719326 at ClinicalTrials.govDocuments that mention this clinical trial
434 Updated clinical data from the melanoma expansion cohort of an ongoing Ph1/1b Study of eganelisib (formerly IPI-549) in combination with nivolumab
https://doi.org/10.1136/jitc-2020-sitc2020.0434
It takes two to TAM-go
https://doi.org/10.1136/gutjnl-2024-334506
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
352 Updated clinical data from the squamous cell carcinoma of the head and neck (SCCHN) expansion cohort of an ongoing Ph1/1b Study of eganelisib (formerly IPI-549) in combination with nivolumab
https://doi.org/10.1136/jitc-2020-sitc2020.0352
Blood TCTP as a potential biomarker associated with immunosuppressive features and poor clinical outcomes in metastatic gastric cancer
https://doi.org/10.1136/jitc-2024-010455
Peptidic microarchitecture-trapped tumor vaccine combined with immune checkpoint inhibitor or PI3Kγ inhibitor can enhance immunogenicity and eradicate tumors
https://doi.org/10.1136/jitc-2021-003564
Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment
https://doi.org/10.1136/jitc-2024-009160
nct00607048 at ClinicalTrials.govDocuments that mention this clinical trial
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
Blood TCTP as a potential biomarker associated with immunosuppressive features and poor clinical outcomes in metastatic gastric cancer
https://doi.org/10.1136/jitc-2024-010455
High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer
https://doi.org/10.1136/jitc-2020-001965
Lifting the innate immune barriers to antitumor immunity
https://doi.org/10.1136/jitc-2020-000695
nct02665416 at ClinicalTrials.govDocuments that mention this clinical trial
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
nct03329950 at ClinicalTrials.govDocuments that mention this clinical trial
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
New emerging targets in cancer immunotherapy: the role of Cluster of Differentiation 40 (CD40/TNFR5)
https://doi.org/10.1136/esmoopen-2019-000510
Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy
https://doi.org/10.1136/jitc-2020-001687
nct05231122 at ClinicalTrials.govDocuments that mention this clinical trial
Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
https://doi.org/10.1136/jitc-2019-000404
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
596 Results from a phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab
https://doi.org/10.1136/jitc-2022-sitc2022.0596
Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model
https://doi.org/10.1136/jitc-2020-000772
nct02480374 at ClinicalTrials.govDocuments that mention this clinical trial
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
nct03393884 at ClinicalTrials.govDocuments that mention this clinical trial
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
nct04660929 at ClinicalTrials.govDocuments that mention this clinical trial
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
nct03834948 at ClinicalTrials.govDocuments that mention this clinical trial
Engineering macrophages for effective and safe targeting of CD47 cancer cells in the tumor microenvironment
https://doi.org/10.1136/jitc-2025-014457
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
315 Characterization of CT-0508, an anti-HER2 chimeric antigen receptor macrophage (CAR-M), manufactured from patients enrolled in the phase 1, first in human, clinical trial of CT-0508
https://doi.org/10.1136/jitc-2022-sitc2022.0315
A phase 1, first-in-human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2-overexpressing solid tumors.
https://doi.org/10.1200/jco.2023.41.16_suppl.tps2666
Adoptively transferred macrophages for cancer immunotherapy
https://doi.org/10.1136/jitc-2024-010437
CARs and beyond: tailoring macrophage-based cell therapeutics to combat solid malignancies
https://doi.org/10.1136/jitc-2021-002741
Scalable generation of functional human iPSC-derived CAR-macrophages that efficiently eradicate CD19-positive leukemia
https://doi.org/10.1136/jitc-2023-007705
nct02216409 at ClinicalTrials.govDocuments that mention this clinical trial
260 CD47 antibody, AO-176 demonstrates potent anti-tumor activity in pre-clinical solid tumor xenografts as a single agent and in combination with multiple classes of therapeutics
https://doi.org/10.1136/jitc-2021-sitc2021.260
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
215 AO-176, a highly differentiated clinical stage anti-CD47 antibody, preferentially binds tumor versus normal cell CD47 when complexed to β1 integrin
https://doi.org/10.1136/jitc-2020-sitc2020.0215
nct03558139 at ClinicalTrials.govDocuments that mention this clinical trial
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
Neuroblastoma: an ongoing cold front for cancer immunotherapy
https://doi.org/10.1136/jitc-2023-007798
nct02953782 at ClinicalTrials.govDocuments that mention this clinical trial
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
nct03990233 at ClinicalTrials.govDocuments that mention this clinical trial
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
Lifting the innate immune barriers to antitumor immunity
https://doi.org/10.1136/jitc-2020-000695
Neutrophil extracellular traps impede cancer metastatic seeding via protease-activated receptor 2-mediated downregulation of phagocytic checkpoint CD24
https://doi.org/10.1136/jitc-2024-010813
nct01685255 at ClinicalTrials.govDocuments that mention this clinical trial
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells
https://doi.org/10.1136/jitc-2022-006567
nct02575807 at ClinicalTrials.govDocuments that mention this clinical trial
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
28 Retrospective pooled analysis of epacadostat clinical studies identifies doses required for maximal pharmacodynamic effect in anti-PD-1 combination studies
https://doi.org/10.1136/jitc-2020-sitc2020.0028
nct02734004 at ClinicalTrials.govDocuments that mention this clinical trial
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
nct02484404 at ClinicalTrials.govDocuments that mention this clinical trial
Potentiation of cancer immunogenicity by targeting PARP
https://doi.org/10.1136/jitc-2024-011056
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies
https://doi.org/10.1136/ijgc-2019-000499
DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment
https://doi.org/10.1136/ijgc-2020-001694
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
https://doi.org/10.1136/jitc-2022-006624
nct02484404 at ClinicalTrials.govDocuments that mention this clinical trial
Potentiation of cancer immunogenicity by targeting PARP
https://doi.org/10.1136/jitc-2024-011056
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies
https://doi.org/10.1136/ijgc-2019-000499
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
https://doi.org/10.1136/jitc-2020-000642
Targeting immune checkpoints in breast cancer: an update of early results
https://doi.org/10.1136/esmoopen-2017-000255
Chemotherapy-free treatment of recurrent advanced ovarian cancer: myth or reality?
https://doi.org/10.1136/ijgc-2022-003719
Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer
https://doi.org/10.1136/jitc-2025-014365
579-D Multiplex imaging of ovarian carcinoma reveals spatial cell interaction patterns predictive of immunotherapy responses
https://doi.org/10.1136/jitc-2023-sitc2023.0579-d
nct03737643 at ClinicalTrials.govDocuments that mention this clinical trial
Potentiation of cancer immunogenicity by targeting PARP
https://doi.org/10.1136/jitc-2024-011056
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies
https://doi.org/10.1136/ijgc-2019-000499
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
https://doi.org/10.1136/jitc-2020-000642
Targeting immune checkpoints in breast cancer: an update of early results
https://doi.org/10.1136/esmoopen-2017-000255
Chemotherapy-free treatment of recurrent advanced ovarian cancer: myth or reality?
https://doi.org/10.1136/ijgc-2022-003719
Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer
https://doi.org/10.1136/jitc-2025-014365
579-D Multiplex imaging of ovarian carcinoma reveals spatial cell interaction patterns predictive of immunotherapy responses
https://doi.org/10.1136/jitc-2023-sitc2023.0579-d
Documents that mention this clinical trial
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
https://doi.org/10.1136/ijgc-2020-001288
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
https://doi.org/10.1136/jitc-2022-005968
First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion
https://doi.org/10.1136/esmoopen-2020-001110
Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial.
https://doi.org/10.1200/jco.2023.41.17_suppl.lba5506
Neoadjuvant immunotherapy of locoregionally advanced solid tumors
https://doi.org/10.1136/jitc-2022-005036
Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study
https://doi.org/10.1136/ijgc-2019-000512
Best original research presented at the 24th European Congress on Gynaecological Oncology—Best of ESGO 2023
https://doi.org/10.1136/ijgc-2023-005132
#1120 Durvalumab with paclitaxel/carboplatin + bevacizumab then maintenance durvalumab, bevacizumab + olaparib in patients with newly diagnosed advanced ovarian cancer without a tumour BRCA1/2 mutation: results from the DUO-O/ENGOT-Ov46/AGO-OVAR 23/GOG-3025 trial
https://doi.org/10.1136/ijgc-2023-esgo.899
Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8<sup>+</sup> TILs based on <i>BRCA1/2</i> mutation status in epithelial ovarian cancers
https://doi.org/10.1136/jitc-2024-009058
Treatment of epithelial ovarian cancer
https://doi.org/10.1136/bmj.m3773
-
Funding
Funding for this research was provided by:
Sotio Biotech
- License Information
